MIRA

MIRA is an early development-stage pharma with zero revenue across its entire history (FY2022–FY2025) and four straight years of losses (-$7.1M, -$12.0M, -$7.9M, -$10.4M). Its own auditor attached a going-concern explanatory paragraph to the FY2025 financials, and the risk section states plainly that the company 'may not generate revenue or achieve a profit for many years, if at all.' The entire investment case rests on two neuroscience candidates — Ketamir-2, only in a Phase 1 healthy-volunteer trial with data still blinded, and MIRA-55, still preclinical and, per the filing, carrying no patent protection — plus a September 2025 acquisition of related-party SKNY whose lead asset is likewise preclinical. This is binary, science-dependent risk of the highest order, and the rubric treats unknowable clinical outcomes on an unprofitable balance sheet as not investable.

The balance sheet looks superficially clean — $6.35M cash, only $702K of liabilities, and a 0.07x liabilities/equity ratio — but that solvency is a mirage of timing. Operating cash burn was -$4.66M in FY2025, so current cash funds barely more than a year of operations, and management explicitly guides that R&D expense 'will increase in the future' as Ketamir-2 moves into the planned 1H2026 Phase 2a CIPN study and MIRA-55 advances to IND-enabling work. The filing concedes 'significant and increasing liquidity needs' requiring additional funding. Meanwhile shares outstanding already jumped 149.9% YoY to 42.0M, driving diluted EPS to -$1.35 and ROE to -100.5% — existing holders are being diluted hard just to keep the lights on, and the next raise into a $0.94 stock will compound the damage.